IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
25.61
+0.82 (3.31%)
Dec 20, 2024, 4:00 PM EST - Market closed
IDEAYA Biosciences Revenue
IDEAYA Biosciences had revenue of $3.92M in the twelve months ending September 30, 2024, down -83.30% year-over-year. In the year 2023, IDEAYA Biosciences had annual revenue of $23.39M, down -54.08%.
Revenue (ttm)
$3.92M
Revenue Growth
-83.30%
P/S Ratio
n/a
Revenue / Employee
$31,629
Employees
124
Market Cap
2.21B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Ardent Health Partners | 5.71B |
CONMED | 1.29B |
Azenta | 656.32M |
NeoGenomics | 644.12M |
Beam Therapeutics | 349.64M |
GeneDx Holdings | 267.23M |
Ligand Pharmaceuticals | 152.42M |
Iovance Biotherapeutics | 90.86M |
IDYA News
- 5 days ago - IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma - PRNewsWire
- 6 days ago - IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers - PRNewsWire
- 11 days ago - IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 - PRNewsWire
- 12 days ago - IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - PRNewsWire
- 13 days ago - IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor - PRNewsWire
- 16 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 17 days ago - Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash - Seeking Alpha
- 20 days ago - IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events - PRNewsWire